Related Experiment Video
Updated: Jul 15, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
A sulfadimidine model to evaluate pharmacokinetics and residues at various concentrations in laying hen
Natthasit Tansakul1, Frank Niedorf, Manfred Kietzmann
1Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine, Hannover Foundation, Buenteweg, 30559 Hannover. Germany. fvetnst@ku.ac.th
Abstract:
Low level intake of drugs from the ingestion of contaminated feed may lead to residue problems in food animals. Sulfadimidine (SDD) was used as a model to determine the residue risk at various doses in laying hens. The drug was administered as a single intravenous injection (100 mg kg(-1) body weight, BW), as a single oral dose (100, 30, 10, 3, 1 mg kg(-1) BW) and via medicated feed for 7 consecutive days (30, 10, 3 mg kg(-1) BW). Drug levels were determined with HPLC-UV for plasma, yolk and albumen. Pharmacokinetic values, which were calculated using a first-order one-compartment model, residue levels and transfer rates into the eggs were found to be dose-dependent. Even low doses of 3 and 1 mg kg(-1) BW resulted in measurable residues in yolk and albumen 1 day after a single oral administration. After ingestion of medicated feed at 3 mg kg(-1) BW, mean drug levels at 0.14 +/- 0.01 microg g(-1) were found in albumen and at 0.09 +/- 0.01 microg ml(-1) in plasma. Generally, the residue levels in albumen and plasma were higher than in yolk. These findings demonstrate a residue risk for the consumer even after low level intake of drugs.
Related Concept Videos
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Pharmacodynamic Models: Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Measurement of Bioavailability: Pharmacokinetic Methods
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
